We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

225 hedge funds and large institutions have $3.27B invested in Neurocrine Biosciences in 2016 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 97 increasing their positions, 75 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

97.13% more ownership

Funds ownership: 0% → 97.13% (+97%)

29% more repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 75

6% less call options, than puts

Call options by funds: $23.6M | Put options by funds: $25.1M

8% less funds holding

Funds holding: 244 → 225 (-19)

14% less funds holding in top 10

Funds holding in top 10: 7 → 6 (-1)

24% less capital invested

Capital invested by funds: $4.32B → $3.27B (-$1.05B)

37% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 41

Holders
225
Holders Change
-19
Holders Change %
-7.79%
% of All Funds
5.63%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.15%
New
26
Increased
97
Reduced
75
Closed
41
Calls
$23.6M
Puts
$25.1M
Net Calls
-$1.48M
Net Calls Change
-$32.7M

Top Buyers

1
Millennium Management
Millennium Management
New York
+$55.6M
2
HM
HealthCor Management
New York
+$44.8M
3
PA
Perceptive Advisors
New York
+$38M
4
Franklin Resources
Franklin Resources
California
+$18M
5
GPP
Great Point Partners
Connecticut
+$16.1M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$153M
2
EAM
Eagle Asset Management
Florida
-$46.3M
3
Citadel Advisors
Citadel Advisors
Florida
-$35.2M
4
American Century Companies
American Century Companies
Missouri
-$25.8M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$17.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
226
Eagle Asset Management
Florida
– -$46.3M -914,500 Closed
Lord, Abbett & Co
227
Lord, Abbett & Co
New Jersey
– -$17.5M -345,748 Closed
BJCM
228
Blue Jay Capital Management
California
– -$11.5M -226,501 Closed
NIP
229
Nicholas Investment Partners
California
– -$8.54M -168,624 Closed
OAC
230
OMERS Administration Corp
Ontario, Canada
– -$5.99M -118,300 Closed
HCMT
231
Highland Capital Management (Texas)
Texas
– -$4.67M -92,257 Closed
PCM
232
Palisade Capital Management
New Jersey
– -$3.43M -67,756 Closed
Balyasny Asset Management
233
Balyasny Asset Management
Illinois
– -$3.17M -62,493 Closed
Ameriprise
234
Ameriprise
Minnesota
– -$3.14M -61,963 Closed
TI
235
Turner Investments
Pennsylvania
– -$2.25M -44,430 Closed
RCP
236
Rothschild Capital Partners
New York
– -$2.01M -39,700 Closed
ACM
237
Asymmetry Capital Management
California
– -$1.91M -37,644 Closed
EIM
238
Essex Investment Management
Massachusetts
– -$1.79M -35,361 Closed
CCM
239
Cadian Capital Management
New York
– -$1.62M -31,956 Closed
DILH
240
Dai-ichi Life Holdings
Japan
– -$1.26M -24,894 Closed
Squarepoint
241
Squarepoint
New York
– -$1.25M -24,611 Closed
LCG
242
Lisanti Capital Growth
New York
– -$1.03M -20,426 Closed
IGIM
243
I.G. Investment Management
Manitoba, Canada
– -$962K -19,000 Closed
SCM
244
Stevens Capital Management
Pennsylvania
– -$758K -14,961 Closed
N
245
Natixis
France
– -$680K -13,424 Closed
SFM
246
Soros Fund Management
New York
– -$573K -11,322 Closed
Janney Montgomery Scott
247
Janney Montgomery Scott
Pennsylvania
– -$452K -8,924 Closed
M&T Bank
248
M&T Bank
New York
– -$358K -7,069 Closed
SSA
249
Schonfeld Strategic Advisors
New York
– -$274K -5,419 Closed
ADEF
250
Adams Diversified Equity Fund
Maryland
– -$223K -4,900 Closed
7 8 9
10
11

NBIX Hedge Fund Activity: Q4 2016 in Review

225 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2016, worth a combined $3.27B — down 24% from $4.32B a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of NBIX and 26 opened new positions — a net loss of 15 holders — while 75 trimmed existing stakes and 97 added.

The largest buyer was Millennium Management, adding an estimated $55.6M. The largest seller was T. Rowe Price Associates, cutting an estimated $153M.

  • 225 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2016, down from 244 in Q3 2016.
  • Funds reported $3.27B of Neurocrine Biosciences stock for Q4 2016, down 24% quarter-over-quarter.
  • 26 funds opened new Neurocrine Biosciences positions in Q4 2016 and 41 closed out, a net change of -15 holders.
  • The largest Neurocrine Biosciences buyer in Q4 2016 was Millennium Management, an estimated $55.6M added.
  • The largest Neurocrine Biosciences seller in Q4 2016 was T. Rowe Price Associates, an estimated $153M sold.

Based on aggregated 13F filings for Q4 2016.